Detalhe da pesquisa
1.
Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.
Ann Surg
; 277(6): e1306-e1312, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35797609
2.
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Lancet Oncol
; 18(6): 770-778, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28495639